NCT03017820 2025-10-08A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaMayo ClinicPhase 1 Recruiting127 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT04635735 2023-03-23Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple MyelomaMemorial Sloan Kettering Cancer CenterPhase 1/2 Terminated3 enrolled 5 charts
NCT03283046 2017-09-20Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple MyelomaM.D. Anderson Cancer CenterPhase 1 Withdrawn